Clinical Trials Logo

Adrenal Tumors clinical trials

View clinical trials related to Adrenal Tumors.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06100367 Recruiting - Clinical trials for Primary Aldosteronism

11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours

Start date: December 30, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

- 10% of patients with hypertension potentially have the treatable condition - primary aldosteronism (PA). This is caused by either bilateral adrenal disease (~40%), managed with lifelong medications; or unilateral disease (~60%), cured with laparoscopic surgery (adrenalectomy). Current diagnosis of PA includes a screening test with aldosterone-renin ratio, followed by a confirmatory salt loading test (in most patients) to demonstrate unsuppressed aldosterone levels. Of note, some patients with suppressed aldosterone after confirmatory tests (also termed low-renin hypertension) may also have unilateral adrenal tumors. - The difficulty with identifying curable unilateral disease is due to adrenal vein sampling (AVS): an invasive, and technically-difficult procedure. An alternative novel imaging, 11C-Metomidate Positron emission tomography-computed tomography (PET-CT), can detect adrenal tumors which are over-producing aldosterone. It is non-invasive, non-operator-dependent, and potentially may identify more patients with curable unilateral disease. The results from our pilot study in 25 patients with confirmed PA (ClinicalTrials.gov NCT03990701, PA_CURE) showed that 11C-Metomidate PET-CT exhibited comparable performance to AVS in subtyping PA, and this should be validated in a larger study. - In addition, 11C-Metomidate is also able to differentiate adrenocortical lesions in the adrenal gland from other lesions found in adrenal tissue, such as adrenomedullary lesions (e.g. pheochromocytoma). - Hence, the investigators hypothesize that 11C-metomidate PET-CT can accurately (1) identify patients with surgically curable unilateral adrenal disease among hypertensive Asians with primary aldosteronism (PA_CURE 2 / PA_MTO EH study) and (2) differentiate adrenocortical lesions from other lesions in patients with adrenal tumors (PA_MTO AT study)

NCT ID: NCT00894335 Recruiting - Adrenal Tumors Clinical Trials

Anesthesia Management of Retroperitoneal Adrenalectomies

Start date: May 2008
Phase: N/A
Study type: Observational

This study is a prospective, perioperative evaluation of hemodynamic and respiratory parameters in patients undergoing retroperitoneoscopic adrenalectomies.

NCT ID: NCT00713115 Recruiting - Adrenal Tumors Clinical Trials

Prospective Randonmized Comparison of Needlescopic Versus Conventional Laparoscopic Adrenalectomy

Start date: June 2008
Phase: N/A
Study type: Interventional

The study is a prospective radonmized comparison between needlescopic adrenalectomy and conventional laparoscopic adrenalectomy for benign adrenal tumors less than 5 cm. The operative success rate, operative time, intraoperative blood loss, intraoperative or postoperative complication, postoperative pain, postoperative hospital stay, convalescence, and wound cosmesis were compared.

NCT ID: NCT00669266 Recruiting - Pheochromocytoma Clinical Trials

Adrenal Tumors - Pathogenesis and Therapy

Start date: September 2002
Phase:
Study type: Observational

The pathogenesis of adrenal tumors is still not fully elucidated and the treatment options for malignant tumors are poor. The current study investigates different aspects of the pathogenesis of adrenal tumors and evaluates different therapeutic options in patients with adrenocortical carcinoma.